Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-14T23:11:07.107Z Has data issue: false hasContentIssue false
  • English
  • Français

Antibiotic Pipeline Coordinators

Published online by Cambridge University Press:  01 January 2021

Enrico Baraldi ,
Olof Lindahl ,
Miloje Savic ,
David Findlay  and
Christine Årdal
Get access Rights & Permissions [Opens in a new window]

Extract

The World Health Organization (WHO) has published a global priority list of antibiotic-resistant bacteria to guide research and development (R&D) of new antibiotics. Every pathogen on this list requires R&D activity, but some are more attractive for private sector investments, as evidenced by the current antibacterial pipeline. A “pipeline coordinator” is a governmental/non-profit organization that closely tracks the antibacterial pipeline and actively supports R&D across all priority pathogens employing new financing tools.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue S1: Incentives to Stimulate Research and Development of New Antibiotics: Detailed Assessments of Select Incentives and Models , Spring 2018 , pp. 25 - 31
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

The Pew Trust, “Antibiotics Currently in Clinical Development,” February 17, 2014, available at <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development> (February 28, 2018).+(February+28,+2018).>Google Scholar
World Health Organization, The World Is Running Out of Antibiotics, WHO Report Confirms, News Release, September 20, 2017, available at <http://www.who.int/mediacentre/news/releases/2017/running-out-antibiotics/en/> (February 28, 2017).+(February+28,+2017).>Google Scholar
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendel-son, M., Monnet, D. L., and Ouellette, M., “Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis,” The Lancet Infectious Diseases, 18, no. 3 (March 2018): 318–327.Google Scholar
CARB-X, The Combatting Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, available at <http://www.carb-x.org/> (February 28, 2018).+(February+28,+2018).>Google Scholar
Theuretzbacher, U., Savic, M., Årdal, C, and Outterson, K., “Market Watch: Innovation in the Preclinical Antibiotic Pipeline,” Nature Reviews: Drug Discovery 16, no. 11 (2017): 744–745.Google Scholar
Theuretzbacher, U., “Antibiotic Innovation for Future Public Health Needs,” Clinical Microbiology and Infection 23, no. 10 (2017): 713–717.Google Scholar
DRIVE-AB Final Report, “Revitalizing the Antibiotic Pipeline: Stimulating Innovation While Driving Sustainable Use and Global Access,” 2018, available at <http://www.imi.europa.eu/projects-results/project-factsheets/drive-ab> (last visited February 28, 2018).+(last+visited+February+28,+2018).>Google Scholar
See CARB-X, supra note 4.Google Scholar
The Global Antibiotic Research and Development (GARDP), available at <https://www.gardp.org/> (last visited February 28, 2018).+(last+visited+February+28,+2018).>Google Scholar
The United States’ Biomedical Advanced Research and Development Authority (BARDA), available at <https://www.phe.gov/about/BARDA/Pages/default.aspx> (last visited February 28, 2018).+(last+visited+February+28,+2018).>Google Scholar
Renwick, M. J., Brogan, D. M. and Mossialos, E., “A Systematic Review and Critical Assessment of Incentive Strategies for Discovery and Development of Novel Antibiotics,” Journal of Antibiotics 69, no. 2 (2016): 73–88.Google Scholar
So, A. D., Gupta, N., Brahmachari, S. K., Chopra, I., Munos, B., Nathan, C., Outterson, K., Paccaud, J. P., Payne, D. J., Peeling, R. W., Spigelman, M., and Weigelt, J., “Towards New Business Models for R&D for Novel Antibiotics,” Drug Resistance Update 14, no. 2 (2011): 88–94.CrossRefGoogle Scholar
Markham, S. K., “Moving Technologies from Lab to Market,” Research-Technology Management 5, no. 6 (2002): 31–42.Google Scholar
Zorzet, A., “Overcoming Scientific and Structural Bottlenecks in Antibacterial Discovery and Development,” Upsala Journal of Medical Sciences 119, no. 2 (2014): 170–175.Google Scholar
Deak, D., Outterson, K., Powers, J. H., and Kesselheim, A. S., “Progress in the Fight against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration–Approved Antibiotics, 2010–2015,” Annals of Internal Medicine 165, no. 5 (2016): 363–372.Google Scholar
“DRIVE-AB Stakeholder Meeting: European Small and Medium Enterprises Focused on Antibacterial Drug Research and Development,” DRIVE-AB, available at <http://drive-ab.eu/wp-content/uploads/2015/02/DRIVE-AB-SME-stake-holder-meeting-report.pdf> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
The European Investment Bank (EIB), available at <http://www.eib.org/> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
Id.Google Scholar
Outterson, K., “New Business Models for Sustainable Antibiotics,” 2014, Centre on Global health Security Working Group Papers, Working Groups on Antimicrobial Resistance, Chatham House, The Royal Institute of International Affairs.Google Scholar
“European Investment Fund, InnovFin Venture Capital — Leaflet for Intermediaries,” available at <http://www.eif.org/news_centre/publications/innovfin-venture-capital-leaflet.htm> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
Okhravi, C., Callegari, S., Kronlid, S. McKeever, , , C., Baraldi, E., Brogan, O. Lindahl, and F. Ciabuschi, “Simulating Market Entry Rewards For Antibiotics Development,” Journal of Law, Medicine & Ethics 46, no. 2, Suppl. (2018): 32–42.CrossRefGoogle Scholar
See Outterson, supra note 19.Google Scholar
World Economic Forum, Insight Report: Global Risks 2014 (2014), available at <http://www3.weforum.org/docs/WEF_GlobalRisks_Report_2014.pdf> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
“InnovFin Infectious Diseases, European Investment Bank,” available at <http://www.eib.org/products/blending/innovfin/products/infectious-diseases.html> (last visited November 8, 2017).+(last+visited+November+8,+2017).>Google Scholar
InnovFin SME Guarantee Facility, available at <http://www.eif.org/what_we_do/guarantees/single_eu_debt_instrument/innovfin-guarantee-facility/index.htm> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
Boston Consulting Group, 2017, “Follow Up Report for the German Guard Initiative. Breaking through the Wall. A Call for Concerted Action on Antibiotic Research and Development,” at 36–37, available at <http://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
, D. M. and Mossialos, E., “A Critical Analysis of the Review on Antimicrobial Resistance Report and the Infectious Disease Financing Facility,” Globalization and Health 12, no. 8 (2016).Google Scholar
Hourd, P. C. and Williams, D. J., “Success in Healthcare Technology Businesses: Coordinating the Value Milestones of New Product Introduction, Financial Stakeholders and Business Growth,” Innovation 8, no. 3 (2006): 229–247.Google Scholar
Savva, N. and Scholtes, S., “Opt-Out Options in New Product Co-development Partnerships,” Production and Operations Management 23, no. 8 (2014): 1370–1386.Google Scholar
Baraldi, E., Ciabuschi, F., Leach, R., Morel, C., and Waluszewski, A., “Exploring the Obstacles to Implementing New Economic Mechanisms Addressing Antibiotic Resistance: A Multi-actor and System-Level Analysis,” American Journal of Law & Medicine 42, nos. 2-3 (2016): 451–486.Google Scholar
European Observatory on Health Systems & Policies, Policies and Incentives for Promoting Innovation in Antibiotic Research (2010), available at <http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
See Renwick et al., supra note 11.Google Scholar
See DRIVE-AB, supra note 16.Google Scholar
See European Observatory on Health Systems & Policies, supra note 31.Google Scholar
The Office of Health Economics, “Incentives for New Drugs to Tackle Anti-Microbial Resistance,” Briefing, available at <https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar
See Zorzet, supra note 14.Google Scholar
See DRIVE-AB, supra note 16.Google Scholar
Freeman, J., Carroll, G. R., and Hannan, M. T., “The Liability of Newness: Age Dependence in Organizational Death Rates,” American Sociological Review (1983) 692–710.CrossRefGoogle Scholar
Friedman, D. and Alper, J., “Technological Challenges in Antibiotic Discovery and Development: A Workshop Summary,” 2014, Chemical Sciences Roundtable, Board on Chemical Sciences and Technology, Division on Earth and Life Studies, National Research Council.Google Scholar
G20 Germany, Shaping an Interconnected World G20 Leaders, Declaration, Hamburg, July 7-8, 2017, available at <http://www.ilo.org/wcmsp5/groups/public/---dgreports/---dcomm/documents/meetingdocument/wcms_562295.pdf> (last visited March 7, 2018).+(last+visited+March+7,+2018).>Google Scholar